Danusertib, an aurora kinase inhibitor

By Meulenbeld Hielke J   Mathijssen Ron HJ   Verweij Jaap   de Wit Ronald   de Jonge Maja JA  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 3, 2012-03 ,pp. : 383-393

Informa Healthcare

Access to resources Recommend Favorite

Bayesian Calibration of a Physiologically Based Pharmacokinetic/Pharmacodynamic Model of Carbaryl Cholinesterase Inhibition

By Nong Andy   Tan Yu-Mei   Krolski Michael   Wang Jiansuo   Lunchick Curt   Conolly Rory   Clewell Harvey  

Journal of Toxicology and Environmental Health, Vol. 71, Iss. 20, 2008-01 ,pp. : 1363-1381

Taylor & Francis Ltd

Access to resources Recommend Favorite

A Pharmacokinetic–Pharmacodynamic Model for Neuromuscular Blocking Agents to Predict Train-of-Four Twitches

By Eleveld Douglas J.   De Haes Ann   Proost Johannes H.   Wierda J. Mark K. H.  

Journal of Pharmacokinetics and Pharmacodynamics, Vol. 30, Iss. 2, 2003-04 ,pp. : 105-118

Springer Publishing Company

Access to resources Recommend Favorite

Validation of a population pharmacokinetic/pharmacodynamic model for 5 -reductase inhibitors

By Trouw R.A.J.   De Wit M.J.   Olsson Gisleskog P.   Hermann D.   Hammarlund-Udenaes M.   Karlsson M.O.  

European Journal of Pharmaceutical Sciences, Vol. 8, Iss. 4, 1999-08 ,pp. : 291-299

Elsevier

Access to resources Recommend Favorite

Ubiquity: a framework for physiological/mechanism-based pharmacokinetic/pharmacodynamic model development and deployment

By Harrold John   Abraham Anson  

Journal of Pharmacokinetics and Pharmacodynamics, Vol. 41, Iss. 2, 2014-04 ,pp. : 141-151

Springer Publishing Company

Access to resources Recommend Favorite